RELATIONSHIP BETWEEN DEVELOPMENT OF DIARRHEA AND THE CONCENTRATION OF SN-38, AN ACTIVE METABOLITE OF CPT-11, IN THE INTESTINE AND THE BLOOD-PLASMA OF ATHYMIC MICE FOLLOWING INTRAPERITONEAL ADMINISTRATION OF CPT-11

被引:152
作者
ARAKI, E
ISHIKAWA, M
IIGO, M
KOIDE, T
ITABASHI, M
HOSHI, A
机构
[1] NATL CANC CTR,DIV CHEMOTHERAPY,CHUO KU,TOKYO 104,JAPAN
[2] NATL CANC CTR,DIV EXPTL ANIM,CHUO KU,TOKYO 104,JAPAN
[3] NATL CANC CTR,DIV PATHOL,CHUO KU,TOKYO 104,JAPAN
来源
JAPANESE JOURNAL OF CANCER RESEARCH | 1993年 / 84卷 / 06期
关键词
SN-38; ATHYMIC MOUSE; DIARRHEA; HEMORRHAGIC COLITIS;
D O I
10.1111/j.1349-7006.1993.tb02031.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Severe diarrhea occurred during daily intraperitoneal administration of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) at a dose of 50 mg/kg in athymic mouse. Serial determination of CPT-11 and 7-ethyl-10-hydroxycamptothecin (SN-38), with the use of an on-line solid extraction HPLC system, demonstrated that much higher levels of the compounds are retained in the intestine and the blood plasma after five consecutive daily injections than after a single injection. Histologic examination of the gastrointestinal tract showed hemorrhagic colitis on day 7 and later after five consecutive daily injections of CPT-11. The direct cause of diarrhea associated with CPT-11 administration is considered to be enterocolitis caused by high levels of SN-38 and/or CPT-11 retained for a long period in the intestine.
引用
收藏
页码:697 / 702
页数:6
相关论文
共 11 条
[1]   CHARACTERIZATION OF A MAMMALIAN MUTANT WITH A CAMPTOTHECIN-RESISTANT DNA TOPOISOMERASE-I [J].
ANDOH, T ;
ISHII, K ;
SUZUKI, Y ;
IKEGAMI, Y ;
KUSUNOKI, Y ;
TAKEMOTO, Y ;
OKADA, K .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (16) :5565-5569
[2]  
FURUTA T, 1988, JPN J CANC CHEMOTHER, V15, P2757
[3]  
KANEDA N, 1990, CANCER RES, V50, P1715
[4]  
KAWATO Y, 1991, CANCER RES, V51, P4187
[5]  
KAWATO Y, 1987, 46TH P JPN CANC ASS, P408
[6]  
KUNIMOTO T, 1987, CANCER RES, V47, P5944
[7]  
NEGORO S, 1991, JPN J CANC CHEMOTHER, V18, P1013
[8]   PHASE-I STUDY AND PHARMACOKINETICS OF CPT-11 WITH 5-DAY CONTINUOUS INFUSION [J].
OHE, Y ;
SASAKI, Y ;
SHINKAI, T ;
EGUCHI, K ;
TAMURA, T ;
KOJIMA, A ;
KUNIKANE, H ;
OKAMOTO, H ;
KARATO, A ;
OHMATSU, H ;
KANZAWA, F ;
SAIJO, N .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (12) :972-974
[9]   AN EARLY PHASE-II STUDY OF CPT-11 - A NEW DERIVATIVE OF CAMPTOTHECIN, FOR THE TREATMENT OF LEUKEMIA AND LYMPHOMA [J].
OHNO, R ;
OKADA, K ;
MASAOKA, T ;
KURAMOTO, A ;
ARIMA, T ;
YOSHIDA, Y ;
ARIYOSHI, H ;
ICHIMARU, M ;
SAKAI, Y ;
OGURO, M ;
ITO, Y ;
MORISHIMA, Y ;
YOKOMAKU, S ;
OTA, K .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (11) :1907-1912
[10]  
Takeuchi S, 1991, JPN J CANC CHEMOTHER, V18, P1681